FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD.
that two abstracts will be presented in oral sessions at the
20th>Annual Meeting of the American Society of Gene
Cell Therapy from May 10-13, 2017 in Washington, D.C. Copies of
the abstracts are attached hereto as Exhibits 99.1 and 99.2,
respectively, and incorporated by reference herein.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Abstract dated May 11, 2017
|
|
|
99.2
|
Abstract dated May 13, 2017
|
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults. FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Recent Trading Information
FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) closed its last trading session up +0.12 at 2.02 with 37,653 shares trading hands.